Thomson Hospital Kota Damansara (THKD), one of the leading private hospitals in Malaysia launched its latest comprehensive cancer facility, Oncology and Nuclear Medicine @ Thomson Hospital – providing both diagnostic and therapeutic capabilities for cancer patients.
The facility houses the Mediso AnyScan SPECT/CT/PET, the first Tri-modality nuclear medicine imaging equipment in the Asia Pacific region.
This revolutionary breakthrough in cancer care was officiated by Yang Berhormat Dato’ Ramanan Ramakrishnan, Member of Parliament for Sungai Buloh and Ms. Wan Nadiah Binti Wan Mohd Abdullah Yaakob, Chief Executive Officer of Thomson Hospital Kota Damansara.
Oncology and Nuclear Medicine @ Thomson Hospital comprises the latest cancer surgical, chemotherapy, radiosurgery and radiotherapy, nuclear medicine diagnostics and theranostics services under one roof.
“According to a report conducted by the World Health Organisation (WHO) in 2020, 48,639 new cancer cases were reported in Malaysia. Cancer incidences in Malaysia are also predicted to double by 2040 where approximately 1 in 10 people in Malaysia will be diagnosed with cancer in their lifetime.
Cancer is a condition that many Malaysians will have to face and it is our responsibility as a healthcare provider to ensure that as many Malaysians as possible are able to survive and live a good quality of life despite a cancer diagnosis,” said Ms. Nadiah.
Oncology & Nuclear Medicine @ Thomson Hospital is designed to house all cancer treatment modalities under one facility to provide multi-disciplinary care with the best experience throughout the entire patient journey.
The facility has performed over 1,200 diagnostic and therapeutic procedures with oncology patients in areas such as cervix, breast, lung, rectum, head, neck and brain. Among these, the radiotherapy team has treated breast cancer patients using the Deep Inspiration Breath Hold (DIBH) technique, and brain cancer with radiotherapy and craniospinal irradiation (CSI).
The facility has also been receiving patients from across Malaysia and Southeast Asia region – indicating a need for such services amongst patients from neighbouring countries.
THKD is constantly innovating to provide the latest diagnostic and therapeutic services for their patients. Nuclear Medicine therapies such as Yittrium-90, Lutetium-177, Ac-225 and high dose I-131 Therapy are in the pipeline, while radiotherapy and radiosurgery services will be further sub-specialised into gynaecology, haematology and paediatric treatments.
THKD also envisions collaborating with other healthcare institutions in Malaysia and other countries in making cancer therapies accessible to them.
“The effective diagnostic tools provide computed tomography for anatomic correlation, which is a needed improvement for cancer care in identifying areas of hypermetabolism illustrated in PET. It involves an injection of a safe radioactive tracer that helps detect diseased cells, as recommended by a specialist.
Meanwhile, we can treat cancers like neuroendocrine tumours, prostate cancer, and thyroid cancer which means, we treat what we see and we see what we treat.” – Dr. Zool Hilmi Bin Awang, Consultant Nuclear Medicine Physician and Head of Nuclear Medicine.
In conjunction with the launch of Oncology & Nuclear Medicine @ Thomson Hospital, THKD will be offering a number of health promotions (for a limited period) which include:
- F-18 FDG PETCT scan at a promotional price of RM1,980 per scan
- Ga-68 PSMA or Ga-68 DOTATE at RM2,600 per scan
- 20 percent discount on cancer screening for patients’ family members
- Free second opinion consultation with our Consultant Clinical Oncologist
- 15 percent discount on Feminine Health screening package
